The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...

The move to self-administration with a syringe and needle, just like how insulin is often taken for diabetes, means a whole ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

When it comes to managing type 2 diabetes and supporting weight loss, patients often face the choice between Semaglutide ...

Please purchase a Premium Subscription to continue reading. To continue, please log in, or sign up for a new account. We offer one free story view per month. If you ...

Novo Nordisk, maker of Ozempic and Wegovy, now has a market capitalization of more than ... paying patients who are willing ...

The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence ...

The current state of weight-loss treatments is about to shift with the forthcoming availability of GLP-1 drugs in the ...

Investors have sent stocks and bonds higher on expectations of a soft landing. But some Republicans think the central bank ...

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...